Identification
- Name
- Doxylamine
- Accession Number
- DB00366 (APRD00937)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. [PubChem]
- Structure
- Synonyms
- 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
- 2-Dimethylaminoethoxyphenylmethyl-2-picoline
- Dossilamina
- Doxilamina
- Doxilminio
- Doxylaminum
- N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
- Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether
- Product Ingredients
Ingredient UNII CAS InChI Key Doxylamine succinate V9BI9B5YI2 562-10-7 KBAUFVUYFNWQFM-UHFFFAOYSA-N - Product Images
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 7 Select Sleep Aid Tablet 25 mg/1 Oral 7 Eleven 2014-08-05 Not applicable US Basic Care Sleep Aid Tablet 25 mg/1 Oral L. Perrigo Company 2018-03-06 Not applicable US Care One Sleep Aid Tablet 25 mg/1 Oral American Sales Company 2004-06-29 Not applicable US CareOne Nighttime Sleep Aid Tablet 25 mg/1 Oral American Sales Company 2016-05-06 Not applicable US Equaline Sleep Aid Tablet 25 mg/1 Oral Supervalu 2004-08-10 2017-12-22 US Good Neighbor Pharmacy Sleep Aid Tablet 25 mg/1 Oral Amerisource Bergen 1997-06-26 Not applicable US Good sense sleep aid Tablet 25 mg/1 Oral L. Perrigo Company 1997-04-14 Not applicable US Harris Teeter Sleep Aid Tablet 25 mg/1 Oral Harris Teeter 2015-11-21 Not applicable US Health Mart Sleep Aid Tablet 25 mg/1 Oral Mc Kesson 2011-11-21 Not applicable US Healthy Accents Sleep Aid Tablet 25 mg/1 Oral Dza Brands, 2011-06-06 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 7 Select Night Time Relief Doxylamine succinate (12.5 mg/30mL) + Acetaminophen (650 mg/30mL) + Dextromethorphan hydrobromide (30 mg/30mL) Solution Oral 7 Eleven 2014-08-05 Not applicable US 7 Select Night Time Relief Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1) Capsule, gelatin coated Oral 7 Eleven 2014-04-17 Not applicable US Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HCl Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Capsule, liquid filled Oral CVS Health 2017-11-30 Not applicable US Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HCl Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Capsule, liquid filled Oral Cvs Pharmacy,inc 2017-07-07 Not applicable US ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and DOXYLAMINE SUCCINATE Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1) Capsule, liquid filled Oral J.P. BUSINESS ENTERPRISE 2014-12-01 Not applicable US Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine Hydrochloride Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Capsule, liquid filled Oral Granules India Limited 2017-07-07 Not applicable US ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, and DOXYLAMINE SUCCINATE Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1) Capsule, liquid filled Oral Spirit Pharmaceuticals, Llc 2009-10-15 Not applicable US Acetaminophen,Dextromethorphan,Doxylamine Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) Capsule, liquid filled Oral Agile Pharmachem 2014-05-01 Not applicable US Acetaminophen/pseudoephedrine/dextromethorphan/doxylamine Doxylamine succinate (6.25 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg) Capsule Oral Apotex Corporation Not applicable Not applicable Canada Alka-Seltzer Plus Day and Night Cold Doxylamine succinate (6.25 mg/1) + Acetylsalicylic acid (325 mg/1) + Acetylsalicylic acid (500 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine bitartrate (7.8 mg/1) + Phenylephrine bitartrate (7.8 mg/1) Kit Bayer Health Care Llc. 2015-01-09 2018-11-01 US - Categories
- Aminoalkyl Ethers
- Antiemetics
- Antihistamines for Systemic Use
- Autonomic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Ethanolamine Derivatives
- Gastrointestinal Agents
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Pyridines
- UNII
- 95QB77JKPL
- CAS number
- 469-21-6
- Weight
- Average: 270.3694
Monoisotopic: 270.173213336 - Chemical Formula
- C17H22N2O
- InChI Key
- HCFDWZZGGLSKEP-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
- IUPAC Name
- dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
- SMILES
- CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1
Pharmacology
- Indication
Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.
- Structured Indications
- Pharmacodynamics
Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.
- Mechanism of action
Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects.
Target Actions Organism AHistamine H1 receptor antagonistHuman UMuscarinic acetylcholine receptor M1 antagonistHuman UNuclear receptor subfamily 1 group I member 3 Not Available Human - Absorption
Readily absorbed via the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic.
- Route of elimination
- Not Available
- Half life
10 hours
- Clearance
- Not Available
- Toxicity
Signs of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Doxylamine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxylamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Doxylamine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxylamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxylamine. Experimental, Illicit 7-Nitroindazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Doxylamine. Experimental Acepromazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Vet Approved Aceprometazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine. Approved Adipiplon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon. Investigational Agomelatine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Doxylamine is combined with Alaproclate. Experimental Alfaxalone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone. Vet Approved Alfentanil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil. Approved, Illicit Allopregnanolone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone. Investigational Alphacetylmethadol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol. Experimental, Illicit Alphaprodine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. Illicit Alprazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam. Approved, Illicit, Investigational Amisulpride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride. Approved, Investigational Amitriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline. Approved Amobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital. Approved, Illicit Amoxapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine. Approved Amperozide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide. Experimental Amphetamine Amphetamine may increase the anticholinergic activities of Doxylamine. Approved, Illicit, Investigational Aripiprazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole. Approved, Investigational Articaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine. Approved Asenapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine. Approved Azaperone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone. Investigational, Vet Approved Azelastine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Baclofen. Approved Barbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital. Illicit Benmoxin Benmoxin may increase the anticholinergic activities of Doxylamine. Withdrawn Benperidol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benperidol. Approved, Investigational Benzocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may decrease the sedative activities of Doxylamine. Approved, Illicit Benzyl alcohol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol. Approved Benzylpenicilloyl Polylysine Doxylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Doxylamine. Approved, Investigational Brexpiprazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Brofaromine Brofaromine may increase the anticholinergic activities of Doxylamine. Experimental Bromazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Illicit, Investigational Bromisoval Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromisoval. Experimental Bromperidol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol. Approved, Investigational Brompheniramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. Approved Brotizolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam. Approved, Investigational, Withdrawn Bupivacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine. Approved, Investigational Buprenorphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone. Approved, Investigational Butabarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Illicit Butacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butacaine. Vet Approved Butalbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butalbital. Approved, Illicit Butamben Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butamben. Approved, Withdrawn Butethal Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butethal. Approved, Illicit Butorphanol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol. Approved, Illicit, Vet Approved Canertinib Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Canertinib. Investigational Carbamazepine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine. Approved, Investigational Carbinoxamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. Approved Carfentanil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol. Approved Caroxazone Caroxazone may increase the anticholinergic activities of Doxylamine. Withdrawn Cetirizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine. Approved Chloral hydrate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide. Approved, Illicit, Investigational Chlormezanone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine. Approved Chlorphenamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Doxylamine. Illicit, Withdrawn Chlorpromazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone. Approved Cinchocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram. Approved Clemastine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine. Approved, Investigational Clidinium Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium. Approved Clobazam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clobazam. Approved, Illicit clomethiazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole. Investigational Clomipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. Approved, Investigational, Vet Approved Clonazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam. Approved, Illicit Clonidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine. Approved Clopenthixol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. Experimental Clorazepate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate. Approved, Illicit Clothiapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clothiapine. Experimental Clozapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine. Approved Cocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine. Approved, Illicit Codeine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Codeine. Approved, Illicit Cyclizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. Approved Cyclobenzaprine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine. Approved Cyclopropane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane. Experimental Cyproheptadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine. Approved Dantrolene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene. Approved, Investigational Dapiprazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Doxylamine is combined with Dapoxetine. Investigational Deramciclane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. Investigational Desflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Desipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine. Approved, Investigational Desloratadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Doxylamine is combined with Desvenlafaxine. Approved, Investigational Detomidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Detomidine. Vet Approved Dexbrompheniramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Dexmedetomidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Doxylamine. Approved, Illicit Dextromoramide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. Experimental, Illicit Dextropropoxyphene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dezocine. Approved, Investigational Diazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether. Experimental Diethylpropion Diethylpropion may decrease the sedative activities of Doxylamine. Approved, Illicit Difenoxin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin. Approved, Illicit Dihydrocodeine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine. Approved, Illicit Dihydroetorphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine. Experimental, Illicit Dihydromorphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. Experimental, Illicit Dimenhydrinate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate. Approved Diphenhydramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Investigational Diphenoxylate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. Approved, Illicit Dixyrazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine. Experimental Doramectin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doramectin. Vet Approved Doxepin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin. Approved, Investigational DPDPE Doxylamine may increase the central nervous system depressant (CNS depressant) activities of DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved, Vet Approved Drotebanol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Doxylamine is combined with Duloxetine. Approved Dyclonine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Ecgonine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine. Experimental, Illicit Ecopipam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. Investigational Efavirenz Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz. Approved, Investigational Eltanolone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone. Investigational Enflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Enflurane. Approved, Investigational, Vet Approved Entacapone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram. Approved, Investigational Estazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Estazolam. Approved, Illicit Eszopiclone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone. Approved, Investigational Ethanol Ethanol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Ethchlorvynol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide. Approved Ethotoin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin. Approved Ethyl carbamate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Withdrawn Ethyl chloride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. Approved, Illicit Ethylmorphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine. Approved, Illicit Etidocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine. Approved Etifoxine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine. Investigational, Withdrawn Etizolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etizolam. Approved Etomidate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Doxylamine is combined with Etoperidone. Withdrawn Etorphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. Illicit, Vet Approved Ezogabine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine. Approved, Investigational Felbamate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate. Approved Fencamfamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine. Approved, Illicit, Withdrawn Fentanyl Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine. Approved, Investigational Flibanserin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin. Approved, Investigational Fluanisone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluanisone. Experimental Fludiazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Illicit Flunarizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine. Approved Flunitrazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine. Approved, Vet Approved Flupentixol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol. Approved, Investigational, Withdrawn Fluphenazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine. Approved Flurazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Illicit, Investigational Fluspirilene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. Approved, Investigational Fluticasone propionate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate. Approved Fluvoxamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine. Approved, Investigational Fosphenytoin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin. Approved, Investigational Fospropofol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol. Approved, Illicit, Investigational Furazolidone Furazolidone may increase the anticholinergic activities of Doxylamine. Approved, Investigational, Vet Approved Gabapentin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin. Approved, Investigational Gabapentin Enacarbil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gepefrine Gepefrine may decrease the sedative activities of Doxylamine. Experimental Gepirone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gepirone. Investigational Glutethimide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide. Approved, Illicit Guanfacine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine. Approved, Investigational Halazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halazepam. Approved, Illicit, Withdrawn Haloperidol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol. Approved Halothane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane. Approved, Vet Approved Harmaline Harmaline may increase the anticholinergic activities of Doxylamine. Experimental Heroin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Heroin. Approved, Illicit, Investigational Hexobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxylamine. Approved, Investigational Hydracarbazine Hydracarbazine may increase the anticholinergic activities of Doxylamine. Experimental Hydrocodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Doxylamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Iloperidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone. Approved Imipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Doxylamine is combined with Indalpine. Investigational, Withdrawn Indiplon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Doxylamine. Approved Iproclozide Iproclozide may increase the anticholinergic activities of Doxylamine. Withdrawn Iproniazid Iproniazid may increase the anticholinergic activities of Doxylamine. Withdrawn Isocarboxazid Isocarboxazid may increase the anticholinergic activities of Doxylamine. Approved Isoflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane. Approved, Vet Approved Ketamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine. Approved, Vet Approved Ketazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam. Approved Ketobemidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. Approved, Investigational Lamotrigine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine. Approved, Investigational Levetiracetam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam. Approved, Investigational Levobupivacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine. Approved, Investigational Levocabastine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. Approved, Investigational Levocetirizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine. Approved Levodopa Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levodopa. Approved Levomethadyl Acetate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Doxylamine is combined with Levomilnacipran. Approved, Investigational Levorphanol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. Approved Lidocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Doxylamine. Approved, Investigational Lithium Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium. Approved Lofentanil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil. Illicit Loprazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. Experimental Loratadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loratadine. Approved, Investigational Lorazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam. Approved Lormetazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam. Approved Loxapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine. Approved Lurasidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Investigational Magnesium sulfate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. Approved, Investigational Mebanazine Mebanazine may increase the anticholinergic activities of Doxylamine. Withdrawn Mebicar Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mebicar. Experimental Meclizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine. Approved Medazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Medazepam. Experimental Medetomidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine. Vet Approved Melatonin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melatonin. Approved, Nutraceutical, Vet Approved Melperone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melperone. Approved, Investigational Mephedrone Mephedrone may decrease the sedative activities of Doxylamine. Investigational Mephentermine Mephentermine may decrease the sedative activities of Doxylamine. Approved Mepivacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine. Approved, Vet Approved Meprobamate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Illicit Meptazinol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol. Experimental Mesoridazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine. Approved, Investigational Metaxalone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. Approved Methadone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone. Approved Methadyl Acetate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may decrease the sedative activities of Doxylamine. Approved, Illicit Methapyrilene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. Withdrawn Methaqualone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone. Illicit, Withdrawn Methocarbamol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol. Approved, Vet Approved Methohexital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital. Approved Methotrimeprazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Doxylamine. Experimental Methsuximide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. Approved Methylecgonine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine. Experimental Methylene blue Methylene blue may increase the anticholinergic activities of Doxylamine. Approved, Investigational Methylphenobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital. Approved Metyrosine Doxylamine may increase the sedative activities of Metyrosine. Approved Midazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam. Approved, Illicit Midomafetamine Midomafetamine may decrease the sedative activities of Doxylamine. Experimental, Illicit, Investigational Milnacipran The risk or severity of adverse effects can be increased when Doxylamine is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the anticholinergic activities of Doxylamine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved, Investigational Mirtazapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA MMDA may decrease the sedative activities of Doxylamine. Experimental, Illicit Moclobemide Moclobemide may increase the anticholinergic activities of Doxylamine. Approved, Investigational Molindone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone. Approved Morphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine. Approved, Investigational Nabilone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone. Approved, Investigational Nalbuphine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. Approved Nefazodone The risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone. Approved, Withdrawn Nialamide Nialamide may increase the anticholinergic activities of Doxylamine. Withdrawn Nitrazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam. Approved Nitrous oxide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide. Approved, Vet Approved Norflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Norflurane. Approved, Investigational Normethadone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Normethadone. Approved, Illicit Nortriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline. Approved Octamoxin Octamoxin may increase the anticholinergic activities of Doxylamine. Withdrawn Olanzapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Approved, Investigational Olopatadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine. Approved Ondansetron Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron. Approved Opium Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Opium. Approved, Illicit Orphenadrine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Investigational Oxazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. Approved Oxethazaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine. Approved, Investigational Oxprenolol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol. Approved Oxybuprocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. Approved, Investigational Oxycodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone. Approved, Illicit, Investigational Oxymorphone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone. Approved, Investigational, Vet Approved Paliperidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. Approved Paraldehyde Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Pargyline Pargyline may increase the anticholinergic activities of Doxylamine. Approved Paroxetine The risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine. Approved, Investigational Penfluridol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Penfluridol. Experimental Pentazocine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Vet Approved Pentobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Perazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine. Approved, Investigational Perospirone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perospirone. Approved Perphenazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine. Approved Pethidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pethidine. Approved Phenazocine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenazocine. Experimental Phenelzine Phenelzine may increase the anticholinergic activities of Doxylamine. Approved Phenibut Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenibut. Experimental Pheniprazine Pheniprazine may increase the anticholinergic activities of Doxylamine. Withdrawn Phenobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital. Approved, Investigational Phenoperidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine. Experimental Phenoxyethanol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol. Approved Phenoxypropazine Phenoxypropazine may increase the anticholinergic activities of Doxylamine. Withdrawn Phentermine Phentermine may decrease the sedative activities of Doxylamine. Approved, Illicit Phenytoin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin. Approved, Vet Approved Pimozide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide. Approved Pipamperone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone. Approved, Investigational Pipotiazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. Approved, Investigational Piritramide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Piritramide. Approved, Investigational Pirlindole Pirlindole may increase the anticholinergic activities of Doxylamine. Approved Pivhydrazine Pivhydrazine may increase the anticholinergic activities of Doxylamine. Withdrawn Pizotifen Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen. Approved Pomalidomide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide. Approved Pramipexole Doxylamine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. Approved Prazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Illicit Pregabalin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin. Approved, Illicit, Investigational Prilocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine. Approved Primidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Primidone. Approved, Vet Approved Procaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the anticholinergic activities of Doxylamine. Approved, Investigational Prochlorperazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine. Approved, Vet Approved Promazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine. Approved, Vet Approved Promethazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine. Approved, Investigational Propanidid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propanidid. Experimental Proparacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine. Approved, Vet Approved Propofol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol. Approved, Investigational, Vet Approved Propoxycaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine. Approved Protriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Proxibarbal Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal. Experimental PSD502 Doxylamine may increase the central nervous system depressant (CNS depressant) activities of PSD502. Investigational Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Doxylamine. Approved Quazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quazepam. Approved, Illicit Quetiapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine. Approved Quinisocaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine. Experimental Raclopride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Raclopride. Investigational Ramelteon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Investigational Rasagiline Rasagiline may increase the anticholinergic activities of Doxylamine. Approved Remifentanil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil. Approved Remoxipride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Withdrawn Reserpine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine. Approved, Investigational Risperidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone. Approved, Investigational Ritanserin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin. Investigational Ritobegron Ritobegron may decrease the sedative activities of Doxylamine. Investigational Romifidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Romifidine. Vet Approved Ropinirole Doxylamine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Rotigotine Doxylamine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxylamine. Approved Safrazine Safrazine may increase the anticholinergic activities of Doxylamine. Withdrawn Scopolamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine. Approved, Investigational Secobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the anticholinergic activities of Doxylamine. Approved, Investigational, Vet Approved Sepranolone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone. Investigational Sertindole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline. Approved Sevoflurane Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Stiripentol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol. Approved Sufentanil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. Approved, Investigational Sulpiride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride. Approved, Investigational Sultopride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sultopride. Experimental Suvorexant Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine. Approved Tasimelteon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon. Approved, Investigational Temazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam. Approved, Investigational Tetrabenazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine. Approved, Investigational Tetracaine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. Approved, Vet Approved Tetrahydropalmatine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine. Investigational Tetrodotoxin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin. Investigational Thalidomide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal. Approved, Vet Approved Thiopental Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental. Approved, Vet Approved Thioridazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine. Approved, Withdrawn Thiothixene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene. Approved Tiagabine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine. Approved, Investigational Tiapride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride. Approved, Investigational Tiletamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine. Vet Approved Tilidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tilidine. Experimental Tizanidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine. Approved, Investigational Tolcapone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone. Approved, Withdrawn Toloxatone Toloxatone may increase the anticholinergic activities of Doxylamine. Approved Topiramate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate. Approved Tramadol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol. Approved, Investigational Tranylcypromine Tranylcypromine may increase the anticholinergic activities of Doxylamine. Approved, Investigational Trazodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone. Approved, Investigational Triazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam. Approved, Investigational Tricaine methanesulfonate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate. Vet Approved Trichloroethylene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene. Approved Trifluoperazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine. Approved, Investigational Trifluperidol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol. Experimental Triflupromazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. Approved, Vet Approved Trimipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine. Approved Triprolidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine. Approved Valproic Acid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine. Approved Veralipride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Veralipride. Experimental Vigabatrin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin. Approved Vinyl ether Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether. Experimental Vortioxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine. Approved, Investigational Xenon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Xenon. Experimental Xylazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Xylazine. Vet Approved Zaleplon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon. Approved, Illicit, Investigational Ziconotide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Doxylamine is combined with Zimelidine. Withdrawn Ziprasidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Zolazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam. Vet Approved Zolpidem Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide. Approved, Investigational Zopiclone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone. Approved Zotepine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001936
- KEGG Drug
- D02327
- PubChem Compound
- 3162
- PubChem Substance
- 46506354
- ChemSpider
- 3050
- ChEBI
- 51380
- ChEMBL
- CHEMBL1004
- Therapeutic Targets Database
- DAP000859
- PharmGKB
- PA449419
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Doxylamine
- ATC Codes
- R06AA59 — Doxylamine, combinations
- R06AA — Aminoalkyl ethers
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 04:04.04 — Ethanolamine Derivatives
- MSDS
- Download (74 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Allergic Rhinitis (AR) / Upper Respiratory Infections 1 3 Completed Prevention Hyperemesis Gravidarum / Pregnancy 1 3 Completed Treatment Nausea and Vomiting of Pregnancy 1 4 Recruiting Treatment Morning Sickness 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amend
- Centurion Labs
- Chattem Chemicals Inc.
- Deltex Pharmaceuticals Inc.
- Duchesnay Inc.
- Perrigo Co.
- Dosage forms
Form Route Strength Tablet, effervescent Oral Tablet, extended release Oral Capsule; kit Oral Capsule Oral Kit Oral Tablet, delayed release Oral Liquid Oral Capsule, liquid filled Oral Syrup Oral Capsule, gelatin coated Oral Tablet, coated Oral Tablet Oral Syrup Oral 9.75 mg/5mL Tablet, film coated Oral Kit; tablet Oral Powder, for solution Oral Solution Oral Tablet Oral 25 mg Kit Tablet Oral 25 mg/1 - Prices
Unit description Cost Unit Doxylamine succinate powder 1.5USD g Unisom sleep aid tablet 0.34USD tablet Sleep aid 25 mg tablet 0.15USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US6340695 No 2001-06-21 2021-06-21 US US7560122 No 1999-01-25 2019-01-25 US US9526703 No 2013-02-18 2033-02-18 US US9375404 No 2013-02-18 2033-02-18 US US9089489 No 2013-02-18 2033-02-18 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) < 25 °C PhysProp boiling point (°C) 139 °C at 5.00E-01 mm Hg PhysProp water solubility 1 g/ml (succinate salt) Not Available logP 2.5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.541 mg/mL ALOGPS logP 2.9 ALOGPS logP 2.96 ChemAxon logS -2.7 ALOGPS pKa (Strongest Basic) 8.87 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 25.36 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 82.24 m3·mol-1 ChemAxon Polarizability 31.09 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9505 Blood Brain Barrier + 0.9491 Caco-2 permeable + 0.746 P-glycoprotein substrate Substrate 0.7449 P-glycoprotein inhibitor I Non-inhibitor 0.5123 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Inhibitor 0.7507 CYP450 2C9 substrate Non-substrate 0.8153 CYP450 2D6 substrate Non-substrate 0.5432 CYP450 3A4 substrate Substrate 0.6801 CYP450 1A2 substrate Non-inhibitor 0.9092 CYP450 2C9 inhibitor Non-inhibitor 0.8957 CYP450 2D6 inhibitor Inhibitor 0.8361 CYP450 2C19 inhibitor Non-inhibitor 0.8764 CYP450 3A4 inhibitor Non-inhibitor 0.6894 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.736 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.9183 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.9218 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8765 hERG inhibition (predictor II) Inhibitor 0.5398
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzylethers
- Direct Parent
- Benzylethers
- Alternative Parents
- Pyridines and derivatives / Heteroaromatic compounds / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Benzylether / Pyridine / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound / Ether / Dialkyl ether / Amine
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- tertiary amine, pyridines (CHEBI:51380)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
- Gene Name
- NR1I3
- Uniprot ID
- Q14994
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 3
- Molecular Weight
- 39942.145 Da
References
- Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Not Available
- Gene Name
- CYP2B
- Uniprot ID
- Q14097
- Uniprot Name
- CYP2B protein
- Molecular Weight
- 43147.81 Da
References
- Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A: Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. [PubMed:8975784]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:59